Insights

6
6
5
5
10
10
9
9
19
19
17
17
8
8
15
15
7
7
11
11
2016
2007
Company (142)University (28)Hospital (10)Research Institution (6)Foundation (1)
1 - 10 of 142
Sort by
Clinical Trial
Clinical Trial IDNCT02772081Start Date2018-11-01Completion Date2023-01-01PhasePhase 3Study TypeInterventionalStatusNot yet recruiting
This study will compare the administration of porcine surfactant (poractant alfa, Curosurf®) through a less invasive method (LISA) using a thin catheter (CHF 6440) during non-invasive ventilation (NIV) (CPAP, NIPPV, BiPAP) with an approved conventional surfactant administration during invasive ventilation and rapid extubation in terms of short term and mid-term safety and efficacy in spontaneously breathing preterm neonates with clinical signs of respiratory distress syndrome (RDS).
Clinical Trial
Clinical Trial IDNCT02970630Start Date2017-01-01Completion Date0022-02-01PhasePhase 2Study TypeInterventionalStatusCompleted
Prospective, single-arm, open-label, multicentre study with the principal aim to estimate tacrolimus pharmacokinetic parameters in elderly de-novo kidney transplant recipients of ECD (Extended Criteria Donor) kidney grafts treated with Envarsus® prolonged release tablets in combination with everolimus tablets.
Clinical Trial
Clinical Trial IDNCT03197818Start Date2016-12-01Completion Date2018-06-01PhasePhase 3Study TypeInterventionalStatusRecruiting
The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort® Turbuhaler® in terms of pulmonary function, as well as to assess its safety.
Clinical Trial
Clinical Trial IDNCT02998879Start Date2016-12-01Completion Date2020-02-01PhasePhase 2Study TypeInterventionalStatusRecruiting
The main objectives of the study are to evaluate safety and efficacy of repeated treatment with recombinant human alfa-mannosidase of patients with alfa-mannosidosis aged less than 6 years
Clinical Trial
Clinical Trial IDNCT03056326Start Date2016-11-01Completion Date2017-07-01PhasePhase 1Study TypeInterventionalStatusCompleted
Human Neutrophil Elastase (HNE) plays a pivotal role in innate immunity and in neutrophilic lung inflammation that characterized many diseases. CHF 6333 is a potent and 24h-durable inhibitor of HNE, developed as Dry Powder Inhaler (DPI) formulation. This study is designed to investigate the tolerability, safety and pharmacokinetics of inhaled CHF6333 DPI in healthy male subjects. The study will comprise two parts: Part 1 will consist of two alternated cohorts of healthy male subjects to asses…
Clinical Trial
Clinical Trial IDNCT02904772Start Date2016-10-01Completion Date2020-09-01PhasePhase 2Study TypeInterventionalStatusWithdrawn
The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD patients treated with alipogene tiparvovec by assessing both the "clinical response" (as defined by a range of parameters), and "the metabolic response" (postprandial CM metabolism) in LPLD patients with and without an immunosuppressant regimen.
Clinical Trial
Clinical Trial IDNCT02787967Start Date2016-08-01Completion Date2017-06-01PhasePhase 2Study TypeInterventionalStatusCompleted
The study will be conducted in asthmatic children aged 5 to 11 years and is based on a single-dose, open-label, randomized, 2-way cross-over design where a Dry Powder Inhaler (DPI) fixed combination of beclometasone dipropionate (BDP) 35 μg plus formoterol fumarate (FF) 4 μg is compared with the free combination of licensed BDP DPI and FF DPI
Clinical Trial
Clinical Trial IDNCT02743013Start Date2016-04-01Completion Date2016-07-01PhasePhase 1Study TypeInterventionalStatusCompleted
This clinical pharmacology study is performed to evaluate the total systemic exposure and the lung availability of CHF 5993 DPI and pMDI with and without valved holding chamber, in healthy volunteers.
Clinical Trial
Clinical Trial IDNCT02676089Start Date2016-03-01Completion Date2018-07-01PhasePhase 3Study TypeInterventionalStatusActive, not recruiting
The purpose of this study is to evaluate the superiority of CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronum bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) and to compare the effect of CHF 5993 200/6/12.5 µg pMDI vs CHF 5993 200/6/12.5 µg plus open-label Tiotropium 2.5µg, in terms of lung functions parameters and rate of exacerbations, …
Clinical Trial
Clinical Trial IDNCT02676076Start Date2016-02-01Completion Date2018-06-01PhasePhase 3Study TypeInterventionalStatusActive, not recruiting
The purpose of this study is to evaluate the superiority of CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronum bromide) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate), in terms of lung functions parameters and rate of exacerbations, as well as to assess its safety and some health economics outcomes.
We found 142 documents that match your Search
Publications: 216
Patents: 739
Clinical Trials: 142

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in